Table 1.
Demographic table containing blood and CSF biomarker measurements of all study subjects.
| Healthy Control | Alzheimer’s disease | P | ||
|---|---|---|---|---|
| Demographics | n = 26 | n = 30 | ||
| Sex, n (%) | female | 13 (50.0) | 14 (46.7) | 1.000 |
| male | 13 (50.0) | 16 (53.3) | ||
| Age | Median (IQR) | 72.0 (68.2 to 78.8) | 73.5 (66.0 to 81.0) | 0.882 |
| Race, n (%) | Asian | 1 (3.8) | 2 (6.7) | 0.506 |
| Black or African | 1 (3.8) | |||
| American | ||||
| White | 24 (92.3) | 28 (93.3) | ||
| APOE Genotype | n = 26 | n = 30 | ||
| ε3/ε3 | 9 (34.6) | 10 (33.3) | 0.968 | |
| ε3/ε4 | 10 (38.5) | 11 (36.7) | ||
| ε4/ε4 | 7 (26.9) | 9 (30.0) | ||
| CSF Biomarkers (pg/mL) | n = 12 | n = 10 | ||
| CSF pTau181 | Median (IQR) | 48.0 (32.4 to 63.1) | 105.4 (83.9 to 163.4) | 0.005 |
| CSF Total Tau | Median (IQR) | 302.1 (216.2 to 450.0) | 720.2 (560.6 to 1117.8) | 0.001 |
| CSF Aß42 | Median (IQR) | 695.7 (567.8 to 883.2) | 556.0 (497.5 to 634.8) | 0.166 |
| CSF Aß40 | Median (IQR) | 9286.5 (8625.5 to 11675.5) | 9156.0 (7913.2 to 9776.8) | 0.692 |
| CSF Aß42/Aß40 | Median (IQR) | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) | 0.187 |
| Aß42/Total Tau | Median (IQR) | 2.1 (1.8 to 3.3) | 0.6 (0.4 to 1.0) | 0.002 |
| Aß40/Total Tau | Median (IQR) | 30.8 (25.8 to 36.5) | 11.6 (8.0 to 15.2) | <0.001 |
| Aß42+Aß40/Total Tau | Median (IQR) | 33.0 (27.8 to 39.9) | 12.3 (8.4 to 16.2) | <0.001 |
| Aß42/pTau | Median (IQR) | 13.4 (11.6 to 23.1) | 4.3 (3.2 to 6.6) | 0.004 |
| Aß42/pTau | Median (IQR) | 200.8 (178.3 to 248.8) | 75.5 (56.5 to 101.5) | 0.001 |
| Aß42+Aß40/pTau | Median (IQR) | 215.0 (191.9 to 268.8) | 79.9 (59.7 to 108.0) | 0.002 |
| Plasma Biomarkers (pg/mL) | n = 23 | n = 27 | ||
| Plasma pTau181 | Median (IQR) | 1.9 (1.7 to 2.3) | 3.5 (2.9 to 4.2) | <0.001 |
Nonparametric Wilcoxon rank sum and Chi square tests comparing measurements between HC and AD groups stratified by APOE genotype; median and IQR. Values shown for biomarkers are in pg/ml.